Oxycodone
Oxycodone is a prescription opioid for pain with high addiction and overdose risk; like other opioids it can stop breathing, and counterfeit "oxy" pills frequently contain fentanyl.
Overview
Oxycodone is a prescription opioid used to treat moderate-to-severe pain, sold on its own (for example as OxyContin) and in combination products such as Percocet (with acetaminophen). It is an effective pain medicine but carries a high potential for misuse, dependence, and addiction, and it was central to the prescription-opioid wave of the overdose crisis. Taken as prescribed under medical supervision it has a role in pain management; misused — taken in higher doses, crushed to defeat extended-release formulations, or obtained outside the medical system — it is dangerous. As with other opioids, the illicit market is now dominated by counterfeit pills: tablets pressed to look like prescription oxycodone (such as "M30s") frequently contain fentanyl instead, in unpredictable and potentially lethal amounts.
Source: MedlinePlus; DEA
Chemistry & mechanism of action
Oxycodone is an opioid agonist: it binds to and activates mu-opioid receptors in the brain and spinal cord, blocking pain signals and producing pain relief along with sedation and, often, euphoria. Activating these receptors also triggers dopamine release that reinforces repeated use, and it suppresses the brain-stem centers that control breathing — which is why opioid overdose kills by stopping respiration. With repeated use the body develops tolerance and physical dependence, so more is needed for the same effect and stopping brings withdrawal. Dependence can develop even with legitimate prescribed use and is distinct from addiction, though it can contribute to it.
Source: NIDA; PubChem CID 5284603
Effects
At therapeutic doses oxycodone relieves pain and commonly causes drowsiness, constipation, nausea, dizziness, dry mouth, and a sense of calm or euphoria. As the dose rises — or when potency is unknown, as with counterfeit pills — the dangerous effects emerge: pinpoint pupils, heavy sedation, confusion, and breathing that becomes slow and shallow or stops. With repeated use, tolerance and physical dependence develop; stopping after regular use brings opioid withdrawal — muscle and bone aches, restlessness, insomnia, sweating, nausea, diarrhea, and strong cravings — intensely uncomfortable but not usually directly life-threatening on its own.
Source: MedlinePlus; NIDA
Risks & harms
Oxycodone's central danger is respiratory depression: too much slows or stops breathing, and the margin shrinks sharply with higher doses, with reduced tolerance (for example after a period of abstinence), and when combined with other depressants. Mixing oxycodone with alcohol, benzodiazepines, or other opioids compounds the suppression of breathing and is a frequent factor in fatal overdoses. The counterfeit-pill problem makes illicit oxycodone especially deadly: pills sold as oxycodone are often fentanyl in disguise, far more potent and impossible to gauge by appearance. Naloxone (Narcan) reverses an oxycodone or fentanyl overdose, is available over the counter in the U.S. since 2023, may require more than one dose when fentanyl is involved, and is safe to give even if opioids turn out not to be the cause. Overdose signs are unresponsiveness, slow or stopped breathing, gurgling or snoring sounds, and blue or grey lips or fingertips — give naloxone if available and call 911 immediately. For poisoning guidance call Poison Control at 1-800-222-1222; for substance-use support the SAMHSA National Helpline is 1-800-662-4357.
Source: NIDA; DEA; SAMHSA
Legal status (US)
In the United States, oxycodone is a Schedule II controlled substance under the Controlled Substances Act: accepted medical uses but a high potential for abuse and severe dependence, so it is tightly regulated, prescriptions cannot be refilled, and diversion or distribution outside the medical system is a serious federal offense. Counterfeit pills sold as oxycodone are illicit drugs regardless of their markings. Internationally, oxycodone is controlled under United Nations drug conventions, with penalties varying by country. For country-by-country legal detail, see our legality pages.
Source: DEA; UN drug control conventions
Drug laws and enforcement change and vary by country. This is not legal advice. Always confirm with the destination’s embassy or official drug authority before traveling, because penalties can be severe, including imprisonment.
Before you travel
Verify current rules with the destination country’s official drug authority and your own country’s embassy before traveling. Find the destination’s U.S. embassy & official country guidance →
Non-U.S. travelers: check your own government’s travel advisory and embassy.
If you’re detained or arrested abroad
Contact your own country’s embassy or consulate in the destination immediately, not the destination’s authorities. U.S. citizens: contact the nearest U.S. embassy/consulate and the U.S. State Department at +1-202-501-4444 (from abroad). If a U.S. citizen is arrested or detained abroad →
Images
Visual references coming soon.
If it’s too intense
If an experience becomes overwhelming, the goal is to stay safe and let it pass, most difficult experiences ease as the drug wears off.
- Get to a calm, safe space with someone you trust who is sober and can stay with you.
- Cool down if you’re overheating, move somewhere cool, remove extra layers, rest. Overheating is especially a risk with stimulants and MDMA.
- Sip water to thirst, but don’t over-hydrate. Drinking large amounts of plain water (especially after MDMA) can dangerously dilute your blood sodium (hyponatremia). Electrolytes help more than volume.
- Slow your breathing, long, slow exhales help settle a racing heart and anxiety.
- A sugary drink, fruit juice, or a snack can ease shakiness and the anxiety that comes with low blood sugar.
- Do not take more, and do not add another substance to manage it. Redosing or adding something else (including a sedative like a benzodiazepine) can make things worse, not better.
With opioids, slowed or stopped breathing is the emergency, if available, give naloxone and call 911 immediately; it can be given while you wait for help.
Source: general harm-reduction guidance from SAMHSA, NIH/NIDA, and MedlinePlus, in our own words. Draft, not yet medically reviewed.
Forensic dossier
Draft · every field is source-cited or marked “Unknown, pending review”Identity
- PubChem CID
- 5284603PubChem PUG-REST ↗ · retrieved 2026-06-18
- IUPAC name
- (4R,4aS,7aR,12bS)-4a-hydroxy-9-methoxy-3-methyl-2,4,5,6,7a,13-hexahydro-1H-4,12-methanobenzofuro[3,2-e]isoquinolin-7-onePubChem PUG-REST ↗ · retrieved 2026-06-18
- Molecular formula
- C18H21NO4PubChem PUG-REST ↗ · retrieved 2026-06-18
- SMILES
- CN1CC[C@]23[C@@H]4C(=O)CC[C@]2([C@H]1CC5=C3C(=C(C=C5)OC)O4)OPubChem PUG-REST ↗ · retrieved 2026-06-18
- InChIKey
- BRUQQQPBMZOVGD-XFKAJCMBSA-NPubChem PUG-REST ↗ · retrieved 2026-06-18
- Synonyms / aliases
- oxycontin, percocet, Dihydrone, Dihydrohydroxycodeinone, Dihydroxycodeinone, Diphydrone, Oxicodona, Endone, Oxanest, (-)-14-Hydroxydihydrocodeinone, Dihydro-14-hydroxycodeinone, OxycodonumPubChem PUG-REST + seed aliases ↗ · retrieved 2026-06-18
Composition
- Composition
- N/A — single compound (see Identity)
Physical / pill characteristics
- Dosage form
- 3 DOSAGE FORMS AND STRENGTHS Oxycodone hydrochloride tablets USP: 5 mg white, round, biconvex, beveled edge tablets de-bossed with 'T' and break line on one sidopenFDA drug label ↗ · retrieved 2026-06-18
- Shape
- Unknown — pending review (verify tablet imprint/shape against NLM Pillbox/DailyMed; N/A if not an oral tablet)
- Color
- Unknown — pending review (verify tablet imprint/shape against NLM Pillbox/DailyMed; N/A if not an oral tablet)
- Imprint
- Unknown — pending review (verify tablet imprint/shape against NLM Pillbox/DailyMed; N/A if not an oral tablet)
- Score
- Unknown — pending review (verify tablet imprint/shape against NLM Pillbox/DailyMed; N/A if not an oral tablet)
Scheduling & legal status
- US schedule
- Unknown — pending review
- International
- Unknown, pending review
Effects, risks & interactions
- Effects
- Oxycodone is a semi-synthetic opioid used for moderate-to-severe pain, familiar from controlled-release products. Acting on opioid receptors, it produces the class's characteristic effects — pain relief, a sense of relaxation, euphoria and drowsiness. Its felt effect and its dangers both scale with the dose and the formulation, and controlled-release forms are designed to release the drug slowly over time rather than all at once.NIDA Opioids + PubChem CID 5284603 ↗ · retrieved 2026-06-18
- Risks
- Oxycodone shares the class's defining hazard — respiratory depression that can be fatal in overdose — and that danger is magnified when slow-release tablets are crushed or altered, delivering their whole load at once, or when the drug is taken alongside other depressants. A major current danger is counterfeiting: illicitly pressed pills sold as oxycodone frequently contain fentanyl, so a tablet obtained outside a pharmacy cannot be assumed to be genuine or to contain what it appears to. Constipation, nausea, tolerance and dependence are common. Given promptly, naloxone can reverse the overdose.NIDA Opioids + PubChem CID 5284603 ↗ · retrieved 2026-06-18
- Interactions
- Oxycodone's label puts co-use with benzodiazepines, alcohol and other depressants first among its dangers — a pairing that can end in deep sedation, respiratory failure, coma and death. Because it is handled by the CYP3A4 and CYP2D6 enzymes, medicines that block them can drive its levels up toward toxicity, while enzyme-inducing ones can sap its effect or unmask withdrawal. Serotonergic drugs, monoamine-oxidase inhibitors and agonist/antagonist opioids each carry their own labelled cautions.DailyMed Oxycodone §7 Drug Interactions ↗ · retrieved 2026-06-18
Pill catalog
Rx/OTC variants · openFDA + DailyMed (public domain) · draft, pending reviewThis drug comes in 272different versions. Make sure you’re looking at the right one, use the search above to find your exact pill by imprint, color, or shape.
Showing 24 of 272 variants
- Strength
- OXYCODONE HYDROCHLORIDE 15 mg/1
- Imprint
- Unknown — pending review
- Color
- Unknown — pending review
- Shape
- Unknown — pending review
- Form
- TABLET
- Labeler
- Asclemed USA, Inc.
- Schedule
- CII
- NDC
- 76420-758 ↗ · 2026-06-18
- Strength
- OXYCODONE HYDROCHLORIDE 15 mg/1
- Imprint
- Unknown — pending review
- Color
- Unknown — pending review
- Shape
- Unknown — pending review
- Form
- TABLET
- Labeler
- Bryant Ranch Prepack
- Schedule
- CII
- NDC
- 72162-1336 ↗ · 2026-06-18
- Strength
- ACETAMINOPHEN 325 mg/1; OXYCODONE HYDROCHLORIDE 10 mg/1
- Imprint
- Unknown — pending review
- Color
- Unknown — pending review
- Shape
- Unknown — pending review
- Form
- TABLET
- Labeler
- Bryant Ranch Prepack
- Schedule
- CII
- NDC
- 72162-1728 ↗ · 2026-06-18
- Strength
- OXYCODONE HYDROCHLORIDE 15 mg/1
- Imprint
- M 15
- Color
- green
- Shape
- ROUND
- Form
- TABLET
- Labeler
- SpecGx LLC
- Schedule
- CII
- NDC
- 0406-8515 ↗ · 2026-06-18
- Strength
- OXYCODONE HYDROCHLORIDE 30 mg/1
- Imprint
- Unknown — pending review
- Color
- Unknown — pending review
- Shape
- Unknown — pending review
- Form
- TABLET
- Labeler
- Bryant Ranch Prepack
- Schedule
- CII
- NDC
- 72162-1337 ↗ · 2026-06-18
- Strength
- OXYCODONE HYDROCHLORIDE 10 mg/1
- Imprint
- Unknown — pending review
- Color
- Unknown — pending review
- Shape
- Unknown — pending review
- Form
- TABLET
- Labeler
- Asclemed USA, Inc.
- Schedule
- CII
- NDC
- 76420-757 ↗ · 2026-06-18
- Strength
- ACETAMINOPHEN 325 mg/1; OXYCODONE HYDROCHLORIDE 5 mg/1
- Imprint
- Unknown — pending review
- Color
- Unknown — pending review
- Shape
- Unknown — pending review
- Form
- TABLET
- Labeler
- Bryant Ranch Prepack
- Schedule
- CII
- NDC
- 63629-8888 ↗ · 2026-06-18
- Strength
- ACETAMINOPHEN 325 mg/1; OXYCODONE HYDROCHLORIDE 7.5 mg/1
- Imprint
- Unknown — pending review
- Color
- Unknown — pending review
- Shape
- Unknown — pending review
- Form
- TABLET
- Labeler
- Bryant Ranch Prepack
- Schedule
- CII
- NDC
- 72162-1338 ↗ · 2026-06-18
- Strength
- ACETAMINOPHEN 325 mg/1; OXYCODONE HYDROCHLORIDE 10 mg/1
- Imprint
- Unknown — pending review
- Color
- Unknown — pending review
- Shape
- Unknown — pending review
- Form
- TABLET
- Labeler
- Proficient Rx LP
- Schedule
- CII
- NDC
- 63187-363 ↗ · 2026-06-18
- Strength
- ACETAMINOPHEN 325 mg/1; OXYCODONE HYDROCHLORIDE 10 mg/1
- Imprint
- WES 203 10 325
- Color
- WHITE
- Shape
- OVAL
- Form
- TABLET
- Labeler
- Eywa Pharma Inc
- Schedule
- CII
- NDC
- 71930-047 ↗ · 2026-06-18
- Strength
- OXYCODONE HYDROCHLORIDE 10 mg/1
- Imprint
- Unknown — pending review
- Color
- Unknown — pending review
- Shape
- Unknown — pending review
- Form
- TABLET
- Labeler
- Quality Care Products LLC
- Schedule
- CII
- NDC
- 35356-839 ↗ · 2026-06-18
- Strength
- ACETAMINOPHEN 325 mg/1; OXYCODONE HYDROCHLORIDE 5 mg/1
- Imprint
- WES 201
- Color
- BLUE
- Shape
- ROUND
- Form
- TABLET
- Labeler
- Eywa Pharma Inc
- Schedule
- CII
- NDC
- 71930-045 ↗ · 2026-06-18
- Strength
- OXYCODONE HYDROCHLORIDE 30 mg/1
- Imprint
- Unknown — pending review
- Color
- Unknown — pending review
- Shape
- Unknown — pending review
- Form
- TABLET
- Labeler
- Bryant Ranch Prepack
- Schedule
- CII
- NDC
- 71335-1245 ↗ · 2026-06-18
- Strength
- ACETAMINOPHEN 325 mg/1; OXYCODONE HYDROCHLORIDE 7.5 mg/1
- Imprint
- WES 202 7 5 325
- Color
- PINK
- Shape
- OVAL
- Form
- TABLET
- Labeler
- Eywa Pharma Inc
- Schedule
- CII
- NDC
- 71930-046 ↗ · 2026-06-18
- Strength
- ACETAMINOPHEN 325 mg/1; OXYCODONE HYDROCHLORIDE 5 mg/1
- Imprint
- Unknown — pending review
- Color
- Unknown — pending review
- Shape
- Unknown — pending review
- Form
- TABLET
- Labeler
- Asclemed USA, Inc.
- Schedule
- CII
- NDC
- 76420-321 ↗ · 2026-06-18
- Strength
- ACETAMINOPHEN 325 mg/1; OXYCODONE HYDROCHLORIDE 2.5 mg/1
- Imprint
- Unknown — pending review
- Color
- Unknown — pending review
- Shape
- Unknown — pending review
- Form
- TABLET
- Labeler
- Asclemed USA, Inc.
- Schedule
- CII
- NDC
- 76420-320 ↗ · 2026-06-18
- Strength
- ACETAMINOPHEN 325 mg/1; OXYCODONE HYDROCHLORIDE 7.5 mg/1
- Imprint
- Unknown — pending review
- Color
- Unknown — pending review
- Shape
- Unknown — pending review
- Form
- TABLET
- Labeler
- Asclemed USA, Inc.
- Schedule
- CII
- NDC
- 76420-322 ↗ · 2026-06-18
- Strength
- ACETAMINOPHEN 325 mg/1; OXYCODONE HYDROCHLORIDE 10 mg/1
- Imprint
- Unknown — pending review
- Color
- Unknown — pending review
- Shape
- Unknown — pending review
- Form
- TABLET
- Labeler
- Asclemed USA, Inc.
- Schedule
- CII
- NDC
- 76420-323 ↗ · 2026-06-18
- Strength
- ACETAMINOPHEN 325 mg/1; OXYCODONE HYDROCHLORIDE 5 mg/1
- Imprint
- Unknown — pending review
- Color
- Unknown — pending review
- Shape
- Unknown — pending review
- Form
- TABLET
- Labeler
- Bryant Ranch Prepack
- Schedule
- CII
- NDC
- 71335-0216 ↗ · 2026-06-18
- Strength
- OXYCODONE HYDROCHLORIDE 15 mg/1
- Imprint
- Unknown — pending review
- Color
- Unknown — pending review
- Shape
- Unknown — pending review
- Form
- TABLET
- Labeler
- ST. MARY'S MEDICAL PARK PHARMACY
- Schedule
- CII
- NDC
- 60760-957 ↗ · 2026-06-18
- Strength
- OXYCODONE HYDROCHLORIDE 5 mg/1
- Imprint
- Unknown — pending review
- Color
- Unknown — pending review
- Shape
- Unknown — pending review
- Form
- TABLET
- Labeler
- ST. MARY'S MEDICAL PARK PHARMACY
- Schedule
- CII
- NDC
- 60760-954 ↗ · 2026-06-18
- Strength
- OXYCODONE HYDROCHLORIDE 10 mg/1
- Imprint
- Unknown — pending review
- Color
- Unknown — pending review
- Shape
- Unknown — pending review
- Form
- TABLET
- Labeler
- ST. MARY'S MEDICAL PARK PHARMACY
- Schedule
- CII
- NDC
- 60760-955 ↗ · 2026-06-18
- Strength
- OXYCODONE HYDROCHLORIDE 15 mg/1
- Imprint
- Unknown — pending review
- Color
- Unknown — pending review
- Shape
- Unknown — pending review
- Form
- TABLET
- Labeler
- ST. MARY'S MEDICAL PARK PHARMACY
- Schedule
- CII
- NDC
- 60760-956 ↗ · 2026-06-18
- Strength
- OXYCODONE HYDROCHLORIDE 30 mg/1
- Imprint
- Unknown — pending review
- Color
- Unknown — pending review
- Shape
- Unknown — pending review
- Form
- TABLET
- Labeler
- Bryant Ranch Prepack
- Schedule
- CII
- NDC
- 71335-2816 ↗ · 2026-06-18
Dosage
Pending medical reviewer
